GlassScriptPhysician profile
Jila Senemar
NPI 1992897821
$5,773.14
in general payments reported to CMS, 2019-2025
23 companies · $4,467 in 2025
The $4,467 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $45.32 · 2021: $257 · 2022: $267 · 2023: $247 · 2024: $283 · 2025: $4,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,423 · Food and Beverage: $997 · Travel and Lodging: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,423.00 |
| Food and Beverage | $997.11 |
| Travel and Lodging | $576.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $4,039.52 | 2025 | Veozah |
| Abbvie INC. | $428.72 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $207.16 | 2023-2025 | Veozah, Myrbetriq |
| Covidien LP | $126.20 | 2019 | |
| Biogen, INC. | $114.04 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $102.09 | 2022-2024 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $96.94 | 2025 | |
| Exeltis, USA INC. | $91.17 | 2022-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $74.79 | 2021-2025 | |
| Gynesonics, INC. | $74.69 | 2021 | |
| Myovant Sciences INC. | $74.32 | 2022 | |
| Evofem Biosciences, INC. | $60.67 | 2025 | Phexxi, Solosec, Phexx |
| Duchesnay USA Incorporated | $42.25 | 2019 | |
| Sumitomo Pharma America, INC. | $41.27 | 2023-2025 | Myfembree, Gemtesa |
| Lilly USA, LLC | $37.99 | 2025 | Mounjaro, Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $25.37 | 2025 | Genexpert |
| Pfizer INC. | $24.49 | 2022 | |
| Optumhealth Care Solutions, LLC | $21.28 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Baxter Healthcare | $20.33 | 2025 | Perclot |
| Coopersurgical, INC. | $19.82 | 2024 | Paragard T 380a |
| Allergan, INC. | $18.96 | 2019 | |
| Organon LLC | $17.57 | 2023 | Nexplanon |
| Alydia Health | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jila Senemar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.